Pharming Group N.V. (PHAR) Form 6-K — Sep 22, 2026

Pharming announced positive Phase II topline data for leniolisib in genetically defined primary immunodeficiencies with immune dysregulation linked to PI3Kδ signaling, accepted as a late-breaking abstract at ESID 2026 (October 14-17, Netherlands). The single-arm, open-label, intra-patient dose-escalation study in 13 patients showed leniolisib was generally well-tolerated with clinical improvements in immune dysregulation, including a mean 26.4% spleen volume reduction and reduced index lesion size, with no new safety signals.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.